Strong Step Forward
JW Pharmaceutical announced on July 20 that it has obtained a patent for the Wnt target hair loss treatment JW0061 from the Australian Patent Office.
This patent is related to a new drug candidate for hair loss treatment based on the Wnt signaling pathway and aims to protect “a new heterocyclic inducer, including its base or isomer, and compositions containing it as an active ingredient.”
The material patent for JW0061 is registered for the second time following Russia last March. JW Pharmaceutical has currently applied for patents in more than ten countries including Korea, the United States, Europe, Japan, and China.
JW0061 is a first-in-class innovative drug candidate that promotes follicle proliferation and hair regeneration by activating the Wnt signaling pathway in skin and follicular stem cells.
The Wnt signaling pathway plays an important role in skin development and follicle formation during embryonic development and is necessary for skin stem cells to change into follicle stem cells and differentiate into follicles. JW Pharmaceutical expects JW0061 to be effective and have excellent preventive effects on hair loss symptoms such as androgenic alopecia and alopecia areata.
JW Pharmaceutical is currently conducting toxicity evaluation according to Good Laboratory Practice (GLP, non-clinical trial regulations) at global institutions with the goal of starting clinical trials of JW0061 in the first half of 2024. In addition, research is being conducted on the production of clinical drugs and the optimization of transdermal formulations.
A representative from JW Pharmaceutical said, “The patent for JW0061, a first-in-class new drug candidate, is being recognized as an original technology in the global market,” and continued, “We will develop JW0061 into a global innovative drug that complements and replaces existing hair loss treatments.”